Melanotan 2

Accelerating

Melanotan 2 appears in 307 indexed publications going back to 1992, including 16 in the past twelve months. 24 registered trials appear on ClinicalTrials.gov, 3 with Australian sites.

307
Indexed publications
16
Past 12 months, against 9 the year before
24
Registered clinical trials
9,345
Monthly readers on Wikipedia, down 14%

On This Figure
Overlaps with afamelanotide, the closely related approved analogue, which carries much of the clinical literature.

Research Activity

Publication history

How much work has been indexed each year, from Europe PMC. Momentum is measured over a trailing twelve months rather than calendar years, so a partial current year never reads as a decline.

20152026

Publications per year. The final bar is the current year, still in progress.

Indexed publications per year
201518
20168
201711
201811
20193
202016
202122
20228
202316
202419
202512
20269
Public Attention

Who is looking it up

Monthly readers of the Melanotan 2 article on English Wikipedia. An independent measure of curiosity, which often moves quite differently from the evidence.

2025-082026-07
Clinical Trials

The registered pipeline

Early Phase 1
0
Phase 1
4
Phase 2
12
Phase 3
4
Phase 4
0

3 trials have a registered Australian site.

Phase distribution across the most recently updated registered trials.

References

Most recent work

The newest indexed records mentioning Melanotan 2, listed by publication date. Titles are shown as published and link to their source. Inclusion here is a record of what exists, not a judgement of what it shows.

  1. 2026-04-16·Journal of controlled release : official journal of the Controlled Release Society

    Heterochiral co-assembly of β-strands and hairpins affords stereocomplexed peptide hydrogels for drug delivery

    Anderson CF, Wang X, Schneider JP. et al.

  2. 2026-01-14·Journal of pharmaceutical and biomedical analysis

    Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide

    Chawathe A, Sharma N. et al.

  3. 2026-03-01·Expert opinion on pharmacotherapy

    New and currently investigated pharmacotherapies for the erythropoietic protoporphyrias: spotlight on dersimelagon and bitopertin

    Barman-Aksözen J, Granata F, Wäscher S et al.

  4. 2026-03-06·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

    Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients

    Seidl-Philipp M, Schratter H, Auer J et al.

  5. 2026-03-02·Photochemistry and photobiology

    Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study

    Shetty N, Quiñonez RL, Ceresnie MS et al.

  6. 2026-02-03·Life (Basel, Switzerland)

    Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report

    Bonchev A. et al.

  7. 2026-02-16·Reports (MDPI)

    Congenital Erythropoietic Porphyria with Persistent Severe Biochemical Abnormalities and a Non-Mutilating Clinical Course: A Case Report

    Peshin S, Takrori E, Khan KS et al.

  8. 2025-11-24·JAAD case reports

    From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria

    Minder AE, Barman-Aksözen J. et al.

In the Catalogue

Melanotan 2 available from Polaris Research

Supplied as research materials for laboratory use. Free express delivery Australia wide.

Sources

Publication data from Europe PMC. Clinical trial data from ClinicalTrials.gov, U.S. National Library of Medicine. Public attention from Wikimedia pageview data. Evidence grades from reptides.co. We report counts and dates from these sources and link every record to its origin, we do not summarise findings. Last synced 2026-08-02.